FDA recalls GLP-1 drugs nationwide

The FDA has announced a nationwide recall of dozens of compounded tirzepatide injections produced by Apothecary Pharma LLC due to potential contamination and quality concerns. The recall affects 22 lots of non-FDA-approved GLP-1 drugs, which are used as lower-cost alternatives to brand-name weight loss medications, though the FDA has warned against their use due to safety risks such as improper storage, dosing errors, and unapproved ingredients. The recall follows previous warnings and inspections highlighting serious sterility issues, while the popularity of compounded GLP-1 medications continues to grow among patients seeking affordable options.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل